China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow Chinese biotech firm Biotheus, securing exclusive development and commercialization rights to Biotheus’ bispecific antibody (BsAb) PM1080 in Greater China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Hansoh will be responsible for the development, regulatory filing, manufacturing, and commercialization of PM1080 in the region.
Deal Financials
Hansoh will pay Biotheus an upfront fee of RMB 50 million (USD 7.1 million) and is committed to making up to RMB 1.418 billion (USD 201.2 million) in commercial milestone payments, along with tiered royalties on net sales. This strategic partnership aims to leverage Hansoh’s development and commercialization capabilities to bring Biotheus’ innovative bispecific antibody to patients in Greater China.
Biotheus and PM1080
Founded in 2018, Biotheus is a biotech company focused on developing treatments for cancer and autoimmune diseases. Its preclinical-stage bispecific antibody PM1080 targets both the EGFR and c-Met pathways, blocking signal transmission and inhibiting tumor growth and survival. PM1080 has demonstrated significant therapeutic potential, making it a promising candidate for the treatment of various cancers and related diseases.-Fineline Info & Tech
